Date published: 2026-4-19

1-800-457-3801

SCBT Portrait Logo
Seach Input

CA I Inhibitors

CA I inhibitors belong to a specific chemical class that is characterized by their ability to selectively target and inhibit the activity of the enzyme carbonic anhydrase I. These inhibitors are designed to interact with the active site of carbonic anhydrase I, thereby disrupting its normal enzymatic function. Carbonic anhydrase I is a zinc metalloenzyme that plays a crucial role in catalyzing the reversible hydration of carbon dioxide to bicarbonate and hydrogen ions. By inhibiting this enzyme, CA I inhibitors can modulate the carbon dioxide hydration process, which has implications in various biological processes. CA I inhibitors are typically small organic molecules that possess specific structural features that enable them to bind tightly to the active site of carbonic anhydrase I. Their chemical structures often include functional groups such as sulfonamides, sulfamates, or sulfamides, which are known to interact with the zinc ion within the enzyme's active site. This interaction disrupts the normal catalytic activity of carbonic anhydrase I, the conversion of carbon dioxide to bicarbonate and hydrogen ions. The inhibition of carbonic anhydrase I by these compounds can have diverse effects on biological systems. Carbonic anhydrase I is found in various tissues and organs, including the kidneys, lungs, and red blood cells. Inhibition of this enzyme may impact processes such as acid-base balance regulation, respiration, and bicarbonate transport. However, it is important to note that the specific physiological implications of CA I inhibition may vary depending on the context and the particular biological system under investigation. In summary, CA I inhibitors are a class of organic compounds that selectively target and inhibit the activity of carbonic anhydrase I. Through their interaction with the enzyme's active site, these inhibitors modulate the carbon dioxide hydration process, potentially affecting various biological processes. The specific implications of CA I inhibition may differ depending on the biological context and the systems involved.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Methocarbamol

532-03-6sc-211809
sc-211809-CW
1 g
1 g
$205.00
$390.00
(0)

Methocarbamol exhibits intriguing properties as a central nervous system depressant, characterized by its ability to modulate neurotransmitter release through allosteric interactions. Its unique steric configuration allows for selective binding to specific receptor sites, influencing synaptic transmission dynamics. The compound's hydrophilic nature enhances its solubility, facilitating rapid distribution in biological systems. Additionally, its kinetic profile suggests a complex interplay with metabolic pathways, affecting its overall bioavailability and efficacy.

Acetazolamide

59-66-5sc-214461
sc-214461A
sc-214461B
sc-214461C
sc-214461D
sc-214461E
sc-214461F
10 g
25 g
100 g
250 g
500 g
1 kg
2 kg
$81.00
$177.00
$434.00
$541.00
$883.00
$1479.00
$2244.00
1
(1)

Acetazolamide is a widely used carbonic anhydrase I inhibitor. It is primarily studied in the research for glaucoma, as it reduces the production of intraocular fluid, thus lowering the intraocular pressure.

Methazolamide

554-57-4sc-235615
1 g
$94.00
3
(1)

Methazolamide is another carbonic anhydrase I inhibitor that works by decreasing the production of aqueous humor, thereby reducing intraocular pressure.

Dorzolamide

120279-96-1sc-337687
1 g
$960.00
2
(0)

Dorzolamide is a topical carbonic anhydrase I inhibitor used in the research of glaucoma. It helps reduce intraocular pressure by inhibiting carbonic anhydrase I in the ciliary body.

Sulthiame

61-56-3sc-474559
sc-474559A
25 mg
250 mg
$357.00
$2497.00
(0)

Sultiame is an carbonic anhydrase I inhibitor that is primarily studied in the research for certain types of epilepsy. It is used as an adjunctive therapy to control seizures and has additional mechanisms of action beyond carbonic anhydrase inhibition.